Jon Zugazagoitia

This paper develops a framework to predict future oncogene amplification or tumour suppressor deletion in cancer using genomic data, achieving an average AUC of 0.87.

This study shows that engineered CD4+ TIL secreting TCE can induce tumor regression in NSCLC PDX models by redirecting non-tumor dominant T cell clones.